BioWorld

June 11, 2007

View Archived Issues

Regeneron Completes Rolling BLA For IL-1 Trap In CAPS

Hoping to introduce the first marketed product for a group of rare chronic inflammatory conditions, Regeneron Pharmaceuticals Inc. completed a rolling biologics license application for its interleukin-1 (IL-1) Trap. (BioWorld Today) Read More

Auxilium Stock Sale: $49.9M To Boost Enzyme Products

Read More

Biotech vs. Big Accounting: New SOX rules may help

Read More

Acorda Raises $67 Million For Second Fampridine-SR Phase III

Read More

NewCo News: Viamet Gets $4 Million Series A For Targeting Metalloenzymes

Read More

Other News To Note

Read More

Clinic Roundup

Read More

Appointments And Advancements

Read More

Financings Roundup

Read More